Home » Stocks » Aditx Therapeutics

Aditx Therapeutics, Inc. (ADTX)

Stock Price: $1.83 USD 0.12 (7.02%)
Updated Sep 25, 2020 4:00 PM EDT - Market closed
After-hours: $1.85 +0.02 (1.09%) Sep 25, 7:31 PM

Stock Price Chart

Key Info

Market Cap 17.35M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 9.48M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 25, 2020
Last Price $1.83
Previous Close $1.71
Change ($) 0.12
Change (%) 7.02%
Day's Open 1.66
Day's Range 1.66 - 1.85
Day's Volume 503,088
52-Week Range 1.62 - 9.58

More Stats

Market Cap 17.35M
Enterprise Value 18.14M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 9.48M
Float 5.54M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 180,678
Short Ratio 0.02
Short % of Float 1.29%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash -790,675
Net Cash / Share -0.08
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$n/a*
*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018
Revenue--
Operating Income-5.87-5.61
Net Income-5.83-5.69
Shares Outstanding3.833.63
Earnings Per Share-1.52-1.57
Operating Cash Flow-0.46-0.39
Free Cash Flow-0.46-0.39
Cash & Equivalents0.000.12
Total Debt0.170.16
Net Cash / Debt-0.16-0.05
Assets0.120.12
Liabilities2.981.65
Book Value-2.85-1.54
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aditx Therapeutics, Inc.
Country United States
Employees 2
CEO Amro Albanna

Stock Information

Ticker Symbol ADTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ADTX
IPO Date June 30, 2020

Description

ADiTx Therapeutics, a life sciences company, focuses on developing nucleic acid-based technologies for addressing the rejection of transplanted organs, autoimmune diseases, and allergies. The company is developing Apoptotic DNA Immunotherapy (ADi), a nucleic acid-based technology that utilizes an approach, which mimics the way the body naturally induces tolerance to its own tissues. It also develops ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. The company has a license agreement with Loma Linda University and Leland Stanford Junior University. ADiTx Therapeutics, Inc. was founded in 2017 and is headquartered in Loma Linda, California.